Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical VRPX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -4.09% | |
| New 52 Week Closing Low | Bearish | -6.26% | |
| Hot IPO Pullback | Bullish Swing Setup | -6.26% | |
| New 52 Week Low | Weakness | -6.26% | |
| Gapped Down | Weakness | -6.26% | |
| Hot IPO Pullback | Bullish Swing Setup | -12.21% | |
| Outside Day | Range Expansion | -12.21% | |
| Hot IPO Pullback | Bullish Swing Setup | -13.90% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | 2 days ago | |
| Down 5% | 2 days ago | |
| Rose Above Previous Day's High | 2 days ago | |
| Outside Day | 2 days ago | |
| Up 5% | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Virpax Pharmaceuticals, Inc. Description
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Classification
Keywords: Pain Drugs Health Sciences Influenza Drug Delivery Pain Management Dosage Forms Euphoriants Analgesics Morphinans Opioids Bupivacaine Drug Delivery Systems Heroin Drug Delivery Technologies Post Traumatic Stress Disorder Morphine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.24 |
| 52 Week Low | 5.25 |
| Average Volume | 216,889 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.22 | ||||
| Resistance 3 (R3) | 6.26 | 6.03 | 6.08 | ||
| Resistance 2 (R2) | 6.03 | 5.82 | 6.01 | 6.03 | |
| Resistance 1 (R1) | 5.71 | 5.69 | 5.60 | 5.67 | 5.99 |
| Pivot Point | 5.48 | 5.48 | 5.42 | 5.46 | 5.48 |
| Support 1 (S1) | 5.16 | 5.27 | 5.05 | 5.12 | 4.79 |
| Support 2 (S2) | 4.93 | 5.14 | 4.91 | 4.75 | |
| Support 3 (S3) | 4.61 | 4.93 | 4.70 | ||
| Support 4 (S4) | 4.57 |
